there are no direct antidotes to oral platelet inhibitors. Current guidelines recommend discontinuation of the P2Y 12 -inhibitor in elective surgical procedures, whereas ASA treatment should be maintained. 4 However, patients on DAPT undergoing acute surgery will have sustained high-grade platelet inhibition during and after the operation. Platelet transfusion is often used to improve haemostasis in patients with ongoing bleeding, but little is known about its efficacy in patients taking platelet inhibitors, or if efficacy varies depending on the type of antiplatelet therapy used. We investigated the effect of allogeneic platelet supplementation on ex vivo platelet aggregation in blood samples from healthy individuals and in coronary artery disease patients treated with different platelet inhibitors, that is, ASA alone or ASA in combination with clopidogrel or ticagrelor.
Methods

Patients
The study included 40 coronary artery disease subjects [mean age 67 (59-78) yr] and 10 healthy age-matched control subjects without antiplatelet therapy [mean age 60 (48-72) yr]. There were three groups on antiplatelet therapy: (i) ASA-treated consecutive patients with stable angina pectoris (n¼10); (ii) ACS patients treated with ASA+clopidogrel (n¼15); and (iii) ACS patients treated with ASA+ticagrelor (n¼15). The time from initiation of DAPT to blood sampling ranged from 20 to 96 h in the ticagrelor+ASA group and from 20 to 192 h in the ASA+ clopidogrel group. Concomitant medications are shown in Table 1 .
ACS patients were included during a time when ticagrelor was being introduced in western Sweden to replace clopidogrel as first-line treatment in ACS patients. During this period, both ACS patients treated with ASA+ticagrelor and ACS patients treated with ASA+clopidogrel were admitted to the tertiary coronary care unit at Sahlgrenska University Hospital from the hospital's own catchment area and surrounding hospitals in western Sweden. The study was not randomized; instead, consecutive patients with the respective treatment were asked to participate after receiving oral and written information and were included after giving written consent.
Characteristics of the study subjects are given in Table 1 . To prevent reactions due to alloimmunization that can occur at transfusion or during pregnancy, only men without previous history of transfusion were included. Further exclusion criteria were a known bleeding disorder, known renal or liver disease, platelet count ,150×10 9 litre
21
, or treatment with glycoprotein IIb/IIIa blocking agents within 6 h. The study was approved by the regional research ethics committee and was performed in accordance with the 1975 Declaration of Helsinki.
Study design
Venous blood samples for aggregability analysis were collected in hirudin-anticoagulated 3 ml tubes (.0.15 mg litre 21 ) 2 h after intake of the morning dose of platelet inhibitor(s). Antiplatelet therapy consisted of 75 mg of ASA once daily; or 75 mg of clopidogrel once daily after a loading dose of 300 mg, and 75 mg of ASA; or 90 mg of ticagrelor twice daily after a loading dose of 180 mg, and 75 mg of ASA. Samples for haemoglobin, haematocrit, and platelet count were also collected. Samples from each subject were prepared by addition of increasing amounts of fresh (,6 h old) allogeneic ABOcompatible apheresis platelet concentrate from the hospital blood bank. Platelets were collected with the Trima Accel system version 6.0 (Terumo BCT, Lakewood, CO, USA) according to the manufacturer's instructions and following national and European guidelines. 5 Before donation, the donor platelet count was .230×10 9 litre
21
. Platelets were collected in autologous plasma. The target concentration was 1600×10 9 litre 21 for each donation. Whole blood to citrate ratio was 10:1. Platelet count in each batch of concentrate was measured and the amount of platelet concentrate needed to achieve consistent doses of added platelets was calculated. Phosphate-buffered saline solution (PBS, 10 mM, pH 7.4) was used to maintain a constant volume of additive. The baseline sample consisted of 1 ml of blood and 300 ml of PBS; the low platelet dose 1 ml of blood, 50 ml of platelets, and 250 ml of PBS; the medium dose 1 ml of blood, 100 ml of platelets, and 200 ml of PBS; and the high platelet dose 1 ml of blood, 150 ml of platelets, and 150 ml of PBS. The numbers of platelets added were 60×10 6 , 120×10 6 , and 180×10
6
, which increased the platelet concentration in the samples by +46, +92, and +138×10 9 litre
21
, respectively. The increase in platelet count was calculated to correspond to the increase in platelet count achieved by in vivo transfusion of 2-5 units of singledonor apheresis platelets to a 70 kg patient.
Analyses
Platelet aggregability was analysed with whole-blood impedance aggregometry (Multiplate Roche Diagnostics, Basel, Switzerland) as described. 6 In the test cell of the aggregometer, 300 ml of whole blood, PBS, and platelet mixture were added to 300 ml of saline solution pre-heated to 378C. Test kits used were ADP high sensitivity kit (ADP final concentration 6.5 mM in combination with prostaglandin E1 final concentration 9.4 nM) for high-sensitivity detection of P2Y 12 -dependent aggregation, ASPI test kit [arachidonic acid (AA) final concentration 0.5 mM] to assess cyclooxygenase-dependent (i.e. ASA-sensitive) platelet aggregation, and TRAP test kit (final concentration of thrombin receptor-activating peptide-6 32 mM) which detects PAR-1 receptor-dependent platelet aggregation and is commonly used to evaluate the effect of glycoprotein IIb/IIIa-inhibiting drugs. The change in impedance when platelets aggregate at the electrodes in the test cell is expressed as a graph where the area under the curve is a quantification of platelet aggregability, and reported in arbitrary aggregation units (AU×min).
Single analyses with one test cell (two electrodes) were performed. The maximum tolerated difference between the two electrodes is 20%. The investigator was not blinded to the patient group. The manufacturer's normal range for ADP-high sensitivity test is 43-100 AU×min, for ASPI test 71-115 AU×min, and for TRAP test 84-128 AU×min.
Statistics
The numbers of included subjects were arbitrarily chosen, since no data were available for a sample size calculation when the study started. All data are presented as mean with 95%
confidence intervals. A P-value of ,0.05 was considered statistically significant. Distribution of data was tested for normality with the Kolmogorov -Smirnov test. Aggregation data were normally distributed. Changes from baseline within a group were analysed with the paired t-test. Group comparisons of aggregability at baseline were made with one-way analysis of variance (ANOVA) (more than two groups) or with Student's t-test (two-group comparisons). Differences in response to the different doses of platelet transfusion between the groups were analysed by ANOVA for repeated measurements followed by the unpaired t-test as post hoc test. For statistical analysis, STATISTICA 10 software was used (StatSoft, Tulsa, OK, USA).
Results
ADP-induced aggregability
There was a significant difference in baseline ADP-induced aggregability between the groups (ANOVA P,0.001) ( Table 2 ). ADPinduced aggregability at baseline was significantly reduced in the ASA+clopidogrel and ASA+ticagrelor groups at baseline compared with healthy and ASA-treated subjects (P,0.001 for all comparisons), while the ASA+clopidogrel and ASA+ticagrelor groups were not significantly different in this respect (P¼0.90).
Platelet supplementation improved ADP-induced aggregability significantly in the ASA+clopidogrel group and in the ASA+ ticagrelor group, but not in the ASA group or in healthy subjects (Table 2) . When ASA+clopidogrel and ASA+ticagrelor-treated samples were compared, the response to platelet supplementation was significantly inferior in the ticagrelor-treated samples at the highest dose of platelets (P¼0.021) (Fig. 1) .
AA-induced aggregability
There was a significant difference in AA-induced aggregability in the different groups at baseline (ANOVA, P,0.001) ( Table 2) . Baseline AA-induced aggregability was significantly reduced in all three groups compared with healthy subjects (P,0.001 in all cases). The AA-induced aggregability at baseline was significantly lower in the ASA+clopidogrel and ASA+ticagrelor groups than in the ASA group (P¼0.001 and 0.006, respectively), while the ASA+clopidogrel and ASA+ticagrelor groups were not significantly different in this respect (P¼0.19). Platelet supplementation increased AA-induced aggregability in all four groups, with the highest response in the ASA group and the lowest response in the ASA+ticagrelor group (Table 2) . In a direct comparison between ASA+clopidogrel and ASA+ ticagrelor, the response to platelet supplementation was significantly inferior in ticagrelor-treated patients at all doses of platelets (P¼0.025, 0.040, and 0.004, respectively) ( Fig. 1) .
TRAP-induced aggregability
There was a significant difference in baseline TRAP-induced aggregability between the different groups (ANOVA, P¼0.002) ( Table 2 ). Baseline TRAP-induced platelet aggregability was significantly reduced in the ASA+clopidogrel and ASA+ ticagrelor groups compared with the ASA group (P¼0.004 and 0.006, respectively) or with healthy subjects (P¼0.012 and 0.017, respectively). The ASA group and healthy subjects were not significantly different in this respect (P¼0.89). Platelet supplementation enhanced TRAP-induced aggregability in all four groups, with the largest increase in the ASA+clopidogrel and ASA+ticagrelor groups. There was no significant difference in response between the ASA+clopidogrel and ASA+ticagrelor groups (P¼0.67) (Fig. 1 ).
Discussion
The main findings in the present study were: (i) platelet supplementation improved platelet aggregability independently of the type of antiplatelet drug treatment; and (ii) platelet supplementation was less effective in samples from patients treated with ASA+ticagrelor than those treated with ASA+clopidogrel within 2 h of last drug intake. Even though platelet transfusion has been used extensively over the years to improve platelet function in bleeding patients on antiplatelet therapy, few investigations have assessed efficacy. 7 -9 Furthermore, there have been no studies in coronary artery disease patients, the main consumers of platelet inhibitors, and possible differences in efficacy depending on target pathway and type of inhibitor have not been addressed. In healthy subjects, three previous studies have investigated the effect of platelet transfusion on the reversibility of platelet inhibition by ASA or ASA in combination with clopidogrel. Di Minno and colleagues 7 found that the platelet inhibition afforded by ASA could be restored ex vivo with moderate doses of platelet transfusion. Vilahur and colleagues 8 showed that platelet doses corresponding to 2-3 units restored ex vivo platelet aggregation in clopidogrel-and ASA-treated healthy subjects. Pruller and colleagues 9 found a partial restitution of platelet function in vivo after supplementation of ASA+clopidogrel-treated healthy subjects with autologous platelets. The present study confirms and extends the results from these three studies. AA-induced aggregation was restored and increased above baseline levels after supplementation with platelet doses corresponding to 2-5 units of platelet transfusion. This effect was observed in healthy subjects without ASA, in ASAtreated patients, and in patients treated with ASA in combination with clopidogrel or ticagrelor. However, the final aggregability with the highest platelet dose was markedly higher in ASAtreated patients than in patients treated with ASA+clopidogrel or ASA+ticagrelor. TRAP-induced aggregability was also enhanced with platelet supplementation to levels above baseline in healthy volunteers, and independentlyof antiplatelet regimen. Interestingly, patients on DAPT with clopidogrel or ticagrelor had 25% lower baseline TRAP-induced aggregability than healthy volunteers and ASA-treated patients. This is most likely a reflection of the fact that the platelet-activating effect of TRAP is partly dependent on ADP released from activated platelets, and that P2Y 12 -inhibitors inhibit this amplifying process. A similar mechanism might also explain the significantly lower AA-induced aggregability observed at baseline in patients on DAPTcompared with those on monotherapy with ASA, despite receiving the same dose of ASA (75 mg daily).
In contrast to AA-and TRAP-induced aggregation, the effect of platelet supplementation on ADP-induced aggregation was less pronounced. Although platelet transfusion improved ADP-dependent aggregability significantly in samples from patients treated with ASA and clopidogrel or ASA and ticagrelor, it did not reach more than 50% of the baseline levels in healthy subjects-even with the highest dose of platelets. This indicates that it is more difficult to restore ADP-dependent aggregability than AA-or TRAP-dependent aggregability, which could indicate a potential problem if bleeding occurs in patients treated with DAPT including a P2Y 12 -inhibitor. The levels of aggregation obtained with the highest platelet dose in clopidogrel-and ticagrelor-treated patients (21 and 16 AU×min, respectively) were also markedly lower than a recently suggested cut-off level for an increased bleeding risk in cardiac surgery patients (31 AU×min). 10 We also observed that platelet supplementation was less effective in samples from ticagrelor-treated patients than from clopidogrel-treated patients, both for ADP-induced and AA-induced aggregability. This might be explained by their different pharmacological properties. Clopidogrel is a thienopyridine that covalently binds to the P2Y 12 -receptor, causing irreversible platelet inhibition, while ticagrelor is a high-affinity ADP analogue that causes reversible inhibition of the receptor.
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Ticagrelor has a faster onset and offset than clopidogrel in patients with stable angina; 12 it causes more effective platelet inhibition than clopidogrel and there are no non-responders. 11 However, the enhanced inhibition with ticagrelor was not confirmed in the present study, where baseline ADP-dependent aggregability was comparable in clopidogrel-and ticagrelortreated patients (P¼0.90). The lack of difference might be explained by the limited number of study subjects, inter-individual variability in platelet aggregation, or both. The present study was performed on blood samples collected ,2 h after the last dose of platelet inhibitor, when the anti-aggregating effects of clopidogrel and ticagrelor would be expected to be at their peak. 11 Ticagrelor should be present in peak plasma concentrations, 12 blocking the P2Y 12 -receptors of the 'fresh' platelets added to the samples (or transfused to the patient). In contrast, the concentration of the active metabolite of clopidogrel is likely low 2 h after ingestion of the drug. 13 Zafar and colleagues 14 recently presented data on the effect of ex vivo platelet supplementation in blood samples from healthy subjects who had received prasugrel. Platelet aggregability increased up to 6 h after drug intake but then was stable. The differences in study design make direct comparisons to the present study impossible, but both studies suggest that it is possible to counteract the antiplatelet effect of P2Y 12 -inhibitors early after intake with platelet transfusion. Future studies should more thoroughly investigate the ability of platelet concentrates to restore aggregability at various time points after discontinuation of the specific P2Y 12 -inhibitors. Limitations of this study include those inherent in an ex vivo study of platelet function, and the extent to which the results can be translated into the clinical setting. We used impedance aggregometry, which utilizes whole blood, although contributions of blood vessels and vascular endothelium are absent. Platelet function was only assessed with multielectrode aggregometry and it is possible that other methods might have yielded different results. Nevertheless, there is satisfactory correlation between multielectrode aggregometry and light transmission aggregometry, the gold standard in the assessment of platelet function. 15 16 Donor platelets were not tested for aggregability before addition to the whole blood samples. It is therefore possible that preexisting platelet dysfunction in the concentrate might have influenced the results. The ADP high sensitivity test kit contains prostaglandin E1, which can reduce platelet aggregability. Platelet dysfunction after addition of platelet concentrate might thus be overestimated. Furthermore, it cannot be assumed that platelet inhibition was at steady state in all ACS patients since treatment times differed.
On the other hand, we measured platelet aggregation in all patients and related the effects of platelet supplementation to individual baseline levels. Finally, baseline aggregation cannot be directly compared with other studies since samples were diluted with PBS to maintain the same degree of haemodilution (before and after platelet supplementation) in all samples. In summary, ex vivo platelet supplementation improves platelet aggregability in blood samples from coronary artery disease patients treated with ASA, ASA+clopidogrel, and ASA+ ticagrelor. AA-induced aggregation, which is used to monitor antiplatelet effects of ASA, was completely restored, while recovery of ADP-dependent aggregation, used to monitor the antiplatelet effects of P2Y 12 -antagonists, was limited ex vivo. AA-and ADP-dependent recovery was reduced in ticagrelortreated patients 2 h after last drug intake compared with clopidogrel-treated patients.
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